# Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T

> **NCT05620732** · NA · RECRUITING · sponsor: **Shenzhen University General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Pancreatic Carcinoma
- Advanced Gastric Carcinoma

## Interventions

- **BIOLOGICAL:** Claudin18.2 CAR-T cells

## Key facts

- **NCT ID:** NCT05620732
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620732, "Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05620732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*